Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
03 Mayo 2024 - 12:48PM
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members,
executives and associated persons
Bagsværd, Denmark, 3 May 2024 — This company
announcement discloses the data of the transaction(s) made in Novo
Nordisk shares by the company’s board members, executives and their
associated persons in accordance with Article 19 of Regulation No.
596/2014 on market abuse.
The company’s board members, executives and their associated
persons have reported the transactions to Novo Nordisk and have
given Novo Nordisk power of attorney on their behalf to publish
trading in Novo Nordisk shares by the company’s board members,
executives and their associated persons.
Please find below a statement of such trading in shares issued
by Novo Nordisk.
|
|
Details of the person discharging managerial
responsibilities/person closely associated |
|
a) |
Name of the Board member/Executive/Associated Person |
Maziar Mike Doustdar |
|
|
2 |
Reason for the notification |
|
|
a) |
Position/status |
Executive Vice President |
|
|
b) |
Initial notification/Amendment |
Initial notification |
|
|
3 |
Details of the issuer |
|
|
a) |
Name |
Novo Nordisk A/S |
|
|
b) |
LEI |
549300DAQ1CVT6CXN342 |
|
|
4 |
Details of the transaction(s) |
|
|
a) |
Description of the financial instrument,type of instrument, |
Shares |
|
|
|
Identification code |
Novo Nordisk B DK0062498333 |
|
|
b) |
Nature of the transaction |
Sale of shares |
|
|
c) |
Price(s) and volume(s) |
|
|
|
|
|
|
|
Price(s) |
Volume(s) |
|
|
|
|
DKK 900.05 |
178 shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
d) |
Aggregated information
|
178 sharesDKK 160,208.90 |
|
|
e) |
Date of the transaction |
2024-05-02 |
|
|
f) |
Place of the transaction |
AQUIS EXCHANGE EUROPE AUCTION ON DEMAND (AOD) |
|
|
|
Details of the person discharging managerial
responsibilities/person closely associated |
|
a) |
Name of the Board member/Executive/Associated Person |
Maziar Mike Doustdar |
|
|
2 |
Reason for the notification |
|
|
a) |
Position/status |
Executive Vice President |
|
|
b) |
Initial notification/Amendment |
Initial notification |
|
|
3 |
Details of the issuer |
|
|
a) |
Name |
Novo Nordisk A/S |
|
|
b) |
LEI |
549300DAQ1CVT6CXN342 |
|
|
4 |
Details of the transaction(s) |
|
|
a) |
Description of the financial instrument,type of instrument, |
Shares |
|
|
|
Identification code |
Novo Nordisk B DK0062498333 |
|
|
b) |
Nature of the transaction |
Sale of shares |
|
|
c) |
Price(s) and volume(s) |
|
|
|
|
|
|
|
Price(s) |
Volume(s) |
|
|
|
|
DKK 900.74 |
10,128 shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
d) |
Aggregated information
|
10,128 sharesDKK 9,122,689.30 |
|
|
e) |
Date of the transaction |
2024-05-02 |
|
|
f) |
Place of the transaction |
AQUIS EXCHANGE EUROPE NON DISPLAY ORDER BOOK (NDOB) |
|
|
|
Details of the person discharging managerial
responsibilities/person closely associated |
|
a) |
Name of the Board member/Executive/Associated Person |
Maziar Mike Doustdar |
|
|
2 |
Reason for the notification |
|
|
a) |
Position/status |
Executive Vice President |
|
|
b) |
Initial notification/Amendment |
Initial notification |
|
|
3 |
Details of the issuer |
|
|
a) |
Name |
Novo Nordisk A/S |
|
|
b) |
LEI |
549300DAQ1CVT6CXN342 |
|
|
4 |
Details of the transaction(s) |
|
|
a) |
Description of the financial instrument,type of instrument, |
Shares |
|
|
|
Identification code |
Novo Nordisk B DK0062498333 |
|
|
b) |
Nature of the transaction |
Sale of shares |
|
|
c) |
Price(s) and volume(s) |
|
|
|
|
|
|
|
Price(s) |
Volume(s) |
|
|
|
|
DKK 900.17 |
2,253 shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
d) |
Aggregated information
|
2,253 sharesDKK 2,028,089.70 |
|
|
e) |
Date of the transaction |
2024-05-02 |
|
|
f) |
Place of the transaction |
AQUIS EXCHANGE EUROPE |
|
|
|
Details of the person discharging managerial
responsibilities/person closely associated |
|
a) |
Name of the Board member/Executive/Associated Person |
Maziar Mike Doustdar |
|
|
2 |
Reason for the notification |
|
|
a) |
Position/status |
Executive Vice President |
|
|
b) |
Initial notification/Amendment |
Initial notification |
|
|
3 |
Details of the issuer |
|
|
a) |
Name |
Novo Nordisk A/S |
|
|
b) |
LEI |
549300DAQ1CVT6CXN342 |
|
|
4 |
Details of the transaction(s) |
|
|
a) |
Description of the financial instrument,type of instrument, |
Shares |
|
|
|
Identification code |
Novo Nordisk B DK0062498333 |
|
|
b) |
Nature of the transaction |
Sale of shares |
|
|
c) |
Price(s) and volume(s) |
|
|
|
|
|
|
|
Price(s) |
Volume(s) |
|
|
|
|
DKK 900.10 |
18,153 shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
d) |
Aggregated information
|
18,153 sharesDKK 16,339,540.90 |
|
|
e) |
Date of the transaction |
2024-05-02 |
|
|
f) |
Place of the transaction |
CBOE EUROPE - DXE ORDER BOOKS (NL) |
|
|
|
Details of the person discharging managerial
responsibilities/person closely associated |
|
a) |
Name of the Board member/Executive/Associated Person |
Maziar Mike Doustdar |
|
|
2 |
Reason for the notification |
|
|
a) |
Position/status |
Executive Vice President |
|
|
b) |
Initial notification/Amendment |
Initial notification |
|
|
3 |
Details of the issuer |
|
|
a) |
Name |
Novo Nordisk A/S |
|
|
b) |
LEI |
549300DAQ1CVT6CXN342 |
|
|
4 |
Details of the transaction(s) |
|
|
a) |
Description of the financial instrument,type of instrument, |
Shares |
|
|
|
Identification code |
Novo Nordisk B DK0062498333 |
|
|
b) |
Nature of the transaction |
Sale of shares |
|
|
c) |
Price(s) and volume(s) |
|
|
|
|
|
|
|
Price(s) |
Volume(s) |
|
|
|
|
DKK 900.14 |
2,800 shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
d) |
Aggregated information
|
2,800 sharesDKK 2,520,380.90 |
|
|
e) |
Date of the transaction |
2024-05-02 |
|
|
f) |
Place of the transaction |
TURQUOISE EUROPE |
|
|
|
Details of the person discharging managerial
responsibilities/person closely associated |
|
a) |
Name of the Board member/Executive/Associated Person |
Maziar Mike Doustdar |
|
|
2 |
Reason for the notification |
|
|
a) |
Position/status |
Executive Vice President |
|
|
b) |
Initial notification/Amendment |
Initial notification |
|
|
3 |
Details of the issuer |
|
|
a) |
Name |
Novo Nordisk A/S |
|
|
b) |
LEI |
549300DAQ1CVT6CXN342 |
|
|
4 |
Details of the transaction(s) |
|
|
a) |
Description of the financial instrument,type of instrument, |
Shares |
|
|
|
Identification code |
Novo Nordisk B DK0062498333 |
|
|
b) |
Nature of the transaction |
Sale of shares |
|
|
c) |
Price(s) and volume(s) |
|
|
|
|
|
|
|
Price(s) |
Volume(s) |
|
|
|
|
DKK 900.00 |
10,437 shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
d) |
Aggregated information
|
10,437 sharesDKK 9,393,300.00 |
|
|
e) |
Date of the transaction |
2024-05-02 |
|
|
f) |
Place of the transaction |
UBS EUROPE SE |
|
|
|
Details of the person discharging managerial
responsibilities/person closely associated |
|
a) |
Name of the Board member/Executive/Associated Person |
Maziar Mike Doustdar |
|
|
2 |
Reason for the notification |
|
|
a) |
Position/status |
Executive Vice President |
|
|
b) |
Initial notification/Amendment |
Initial notification |
|
|
3 |
Details of the issuer |
|
|
a) |
Name |
Novo Nordisk A/S |
|
|
b) |
LEI |
549300DAQ1CVT6CXN342 |
|
|
4 |
Details of the transaction(s) |
|
|
a) |
Description of the financial instrument,type of instrument, |
Shares |
|
|
|
Identification code |
Novo Nordisk B DK0062498333 |
|
|
b) |
Nature of the transaction |
Sale of shares |
|
|
c) |
Price(s) and volume(s) |
|
|
|
|
|
|
|
Price(s) |
Volume(s) |
|
|
|
|
DKK 912.15 |
11,051 shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
d) |
Aggregated information
|
11,051 sharesDKK 10,080,130.60 |
|
|
e) |
Date of the transaction |
2024-05-02 |
|
|
f) |
Place of the transaction |
NASDAQ COPENHAGEN A/S |
|
Novo Nordisk is a leading global healthcare company, founded in
1923 and headquartered in Denmark. Our purpose is to drive change
to defeat serious chronic diseases, built upon our heritage in
diabetes. We do so by pioneering scientific breakthroughs,
expanding access to our medicines, and working to prevent and
ultimately cure disease. Novo Nordisk employs about 63,400 people
in 80 countries and markets its products in around 170 countries.
Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B).
Its ADRs are listed on the New York Stock Exchange (NVO). For more
information, visit novonordisk.com, Facebook, Instagram, X,
LinkedIn and YouTube.
Contacts for further information
|
Media: |
|
| Ambre
James-Brown +45 3079 9289abmo@novonordisk.com |
Liz
Skrbkova (US)+1 609 917 0632lzsk@novonordisk.com |
|
Investors: |
|
| Daniel
Muusmann Bohsen+45 3075 2175 dabo@novonordisk.com |
Jacob
Martin Wiborg Rode+45 3075 5956jrde@novonordisk.com |
| David
Heiberg Landsted +45 3077 6915 dhel@novonordisk.com |
Mark
Joseph Root (US) +1 848 213 3219mjhr@novonordisk.com |
| Sina
Meyer +45 3079 6656 azey@novonordisk.com |
|
Company announcement No 36 / 2024
Novo Nordisk (TG:NOV)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Novo Nordisk (TG:NOV)
Gráfica de Acción Histórica
De May 2023 a May 2024
